<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Deposition of beta-amyloid (Abeta) is an early pathogenic event in <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD) </plain></SENT>
<SENT sid="1" pm="."><plain>We measured Abeta42 and Abeta40 in cerebrospinal fluid (CSF) in a population-based sample of 85-year-olds, 27 demented and 35 non-<z:e sem="disease" ids="C0860630" disease_type="Mental or Behavioral Dysfunction" abbrv="">demented</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>During the following 3 years, 7 of the 35 non-<z:e sem="disease" ids="C0860630" disease_type="Mental or Behavioral Dysfunction" abbrv="">demented</z:e> individuals had developed <z:hpo ids='HP_0000726'>dementia</z:hpo>, while 28 remained non-<z:e sem="disease" ids="C0860630" disease_type="Mental or Behavioral Dysfunction" abbrv="">demented</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Reduced CSF levels of both Abeta42 (p = 0.001) and Abeta40 (p = 0.0001) were found in patients with manifest AD and vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> at the age of 85 </plain></SENT>
<SENT sid="4" pm="."><plain>Non-<z:e sem="disease" ids="C0860630" disease_type="Mental or Behavioral Dysfunction" abbrv="">demented</z:e> individuals who developed <z:hpo ids='HP_0000726'>dementia</z:hpo> during follow-up had lower levels of CSF- Abeta42 (p = 0.003), but not CSF-Abeta40 (p = 0.96), than those who remained non-<z:e sem="disease" ids="C0860630" disease_type="Mental or Behavioral Dysfunction" abbrv="">demented</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The odds ratio for development of <z:hpo ids='HP_0000726'>dementia</z:hpo> was 8.2 (p = 0.027) for individuals in the lower 50th percentile of CSF-Abeta42, while none of those in the highest 33rd percentile of CSF-Abeta42 developed <z:hpo ids='HP_0000726'>dementia</z:hpo> during follow-up </plain></SENT>
<SENT sid="6" pm="."><plain>There were no significant differences between carriers and non-carriers of the <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> E epsilon4 allele regarding CSF-Abeta42 or CSF-Abeta40 </plain></SENT>
<SENT sid="7" pm="."><plain>Our study suggests that low CSF-Abeta42 is found also in an unselected population-based sample of old <z:e sem="disease" ids="C0860630" disease_type="Mental or Behavioral Dysfunction" abbrv="">demented</z:e> patients and provides the first evidence of a disturbance in the metabolism of Abeta, specifically involving Abeta42, before the <z:hpo ids='HP_0003674'>onset</z:hpo> of clinical symptoms in AD </plain></SENT>
</text></document>